Fundraising Fox
Affinia Therapeutics
Waltham, US · Founded 2019 · Delaware corporation · 35 employees on LinkedIn · 8 known investors
Find your way into Affinia Therapeutics
993 people in our graph can introduce you to the Affinia Therapeutics team.
Sign up to see every warm intro you have to Affinia Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Affinia Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.
Founders & leadership
Affinia Therapeutics was founded in 2019 by Luc Vandenberghe, Aaron Tward, M.D., Ph.D., Botond Roska, M.D., Ph.D., and Luk Vandenberghe, Ph.D..
Investors · 8
How we know: Atlas Venture's portfolio page · a partner's Signal profile · funding news · press coverage · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Eight Roads Ventures's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$170.1M disclosed across 4 rounds · 2019–2025
▶$13.3MraisedOct 2025 · 20 investors · OtherRule 506(b)
- Carole FaigDirector
- Rami DaoudExecutive Officer
- Robert WeisskoffDirector
- Diana BrainardDirector
- Rick ModiExecutive Officer, Director
- David GrayzelDirector
- Luc VandenbergheDirector
- Elliott SigalDirector
- Edward MathersDirector
- Sean NolanDirector
- Offering amount
- $45M
- Amount sold
- $13.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$110MraisedMay 2021 · 22 investors · OtherRule 506(b)
- Laura RichmanExecutive Officer
- Rick ModiExecutive Officer, Director
- Petra KaufmannExecutive Officer
- Robert AboudExecutive Officer
- Paula CobbExecutive Officer
- Edward MathersDirector
- Sean NolanDirector
- Caroline StoutDirector
- Elliot SigalDirector
- Rob MayExecutive Officer
- Charles AlbrightExecutive Officer
- Luc VandenbergheDirector
- Robert WeisskoffDirector
- David GrayzelDirector
- Offering amount
- $110M
- Amount sold
- $110M
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$38.5MraisedMar 2020 · 16 investors · OtherRule 506(b)
- Robert AboudExecutive Officer
- Robert JohnsonExecutive Officer
- Sean NolanDirector
- Luc VandenbergheDirector
- Rick ModiExecutive Officer, Director
- David GrayzelDirector
- Robert WeisskoffDirector
- Edward MathersDirector
- Offering amount
- $68.5M
- Amount sold
- $38.5M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$8.3MraisedNov 2019 · 14 investors · OtherRule 506(b)
- Luk VandenbergheDirector
- Rick ModiExecutive Officer
- Offering amount
- $8.3M
- Amount sold
- $8.3M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as Affinia Therapeutics.
In the news
Frequently asked questions
- What does Affinia Therapeutics do?
- Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions. The company uses AI and structural modeling to redesign viral delivery vectors for one-time-dose genetic medicines across rare and prevalent diseases.
- Who founded Affinia Therapeutics?
- Affinia Therapeutics was founded by Luc Vandenberghe, Aaron Tward, M.D., Ph.D., Botond Roska, M.D., Ph.D., Luk Vandenberghe, Ph.D. in 2019.
- Who are Affinia Therapeutics's investors?
- Affinia Therapeutics's investors include Atlas Venture, EcoR1 Capital, Eight Roads Ventures, F-Prime Capital, GV (Google Ventures), New Enterprise Associates (NEA), TCG Crossover, NEA Secondary.
- How much funding has Affinia Therapeutics raised?
- Affinia Therapeutics has disclosed $170.1M raised across 4 rounds.
- Where is Affinia Therapeutics headquartered?
- Affinia Therapeutics is headquartered in Waltham, US.